

Tafamidis for treating transthyretin amyloidosis with cardiomyopathy

Information for the public

Published: 19 June 2024

www.nice.org.uk

Tafamidis (Vyndaqel) is available on the NHS. It is a possible treatment for wild-type (develops with age) or hereditary transthyretin amyloidosis with cardiomyopathy in adults.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on amyloidosis](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Amyloidosis UK](#), info@amyloidosisuk.org
- [Cardiomyopathy UK](#), 0800 018 1024

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6163-4